"Clinical Utility of HIV-IgA Immunoblot Assay in the Early Diagnosis of" Perinatal HIV Infection

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

"Clinical Utility of HIV-IgA Immunoblot Assay in the Early Diagnosis of" Perinatal HIV Infection

Journal of the American Medical Association (12/25/91) Vol. 266, No. 24, P. 3443
Landesman, Sheldon et al.

Abstract: Dr. Sheldon Landesman of State University of New York Health Science Center and his associates conducted a study to assess the benefit of testing asymptomatic HIV-infected infants with the HIV-IgA Immunoblot assay. Children born to HIV-infected women and noninfected women were examined with HIV-IgA immunoblot assays at 1 month, 3 months, and 6 months of age. The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for 18 seroreverting, noninfected children born to infected women, the assay brought negative results at 1 month, 3 months, and 6 months of age. There were no false positive results in the total 88 serum samples from noninfected infants with positive predictive value of the assay at 100 percent. The HIV-IgA immunoblot assay can allow therapy to be administered before the onset of AIDS because it can detect infection early in children, the researchers conclude.

911225
AD912298

Copyright © 1991 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.